Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Feature Papers in Section "Cancer Biomarkers" in 2023–2024
share announcement

Feature Papers in Section "Cancer Biomarkers" in 2023–2024

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 604

Special Issue Editor

Prof. Dr. Maxim V. Berezovski

E-Mail Website
Guest Editor
Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
Interests: glioblastoma; lung cancer; molecular diagnostics; circulating tumor cells; tumor-derived exosomes; aptamers; proteomics; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite significant advances in the understanding and treatment of cancers, early detection and personalized therapeutic strategies remain essential in improving patients’ outcomes. Cancer biomarkers are crucial tools in this endeavor, providing insights that guide both research and clinical practice. Recognizing the critical role that biomarkers play, we are pleased to present this Special Issue dedicated exclusively to the latest research and advancements in cancer biomarkers.

The topics of interest include, but are not limited to:

Biomarkers Discovery: Exploring new molecular, genetic, and proteomic markers, which could serve as indicators of cancer initiation, progression, or responses to therapy.

Biomarker Validation and Clinical Implementation: Addressing the challenges and methodologies associated with translating laboratory findings into clinically applicable tools.

Precision Medicine and Targeted Therapies: Examining how cancer biomarkers are driving individualized treatment plans that cater to the unique characteristics of each patient's cancer.

Innovations in Detection and Analysis: Surveying the technological advancements that are enabling more precise, reliable, and cost-effective biomarker evaluation.

This Special Issue brings together a diverse array of contributions from prominent researchers, clinicians, and experts in oncology, genetics, biochemistry, and other interdisciplinary fields. The collaborative nature of these works illuminates the multifaceted approach required to realize the full potential of cancer biomarkers. Original articles, systematic reviews, and review papers are all welcomed. The aim is to have a collection of at least 10 articles, which we would assist you with, and the Special Issue may printed in book form if this goal is achieved.

We look forward to receiving your contributions.

Prof. Dr. Maxim V. Berezovski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • RNA and miRNA biomarkers
  • DNA biomarkers
  • cell-free DNA
  • protein biomarkers
  • metabolomic biomarkers
  • mutational biomarkers
  • circulating tumor cell (CTC) biomarkers
  • tumor-derived extracellular vesicle (tEV) biomarkers
  • cellular biomarkers
  • imaging biomarkers
  • clinical biomarkers
  • biomarkers of drug response
  • biomarkers of genetic predisposition to cancer
  • epigenetic biomarkers
  • biomarkers of cancer outcomes

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2758 KiB  
Article
Microsatellite Instability Testing and Prognostic Implications in Colorectal Cancer
by Vincent Ho, Liping Chung, Kate Wilkinson, Yafeng Ma, Tristan Rutland, Vivienne Lea, Stephanie H. Lim, Askar Abubakar, Weng Ng, Mark Lee, Tara L. Roberts, Therese M. Becker, Scott Mackenzie, Wei Chua and Cheok Soon Lee
Cancers 2024, 16(11), 2005; https://doi.org/10.3390/cancers16112005 (registering DOI) - 25 May 2024
Viewed by 123
Abstract
Given the crucial predictive implications of microsatellite instability (MSI) in colorectal cancer (CRC), MSI screening is commonly performed in those with and at risk for CRC. Here, we compared results from immunohistochemistry (IHC) and the droplet digital PCR (ddPCR) MSI assay on formalin-fixed [...] Read more.
Given the crucial predictive implications of microsatellite instability (MSI) in colorectal cancer (CRC), MSI screening is commonly performed in those with and at risk for CRC. Here, we compared results from immunohistochemistry (IHC) and the droplet digital PCR (ddPCR) MSI assay on formalin-fixed paraffin-embedded tumor samples from 48 patients who underwent surgery for colon and rectal cancer by calculating Cohen’s kappa measurement (k), revealing high agreement between the methods (k = 0.915). We performed Kaplan–Meier survival analyses and univariate and multivariate Cox regression to assess the prognostic significance of ddPCR-based MSI and to identify clinicopathological features associated with CRC outcome. Patients with MSI-high had better overall survival (OS; p = 0.038) and disease-free survival (DFS; p = 0.049) than those with microsatellite stability (MSS). When stratified by primary tumor location, right-sided CRC patients with MSI-high showed improved DFS, relative to those with MSS (p < 0.001), but left-sided CRC patients did not. In multivariate analyses, MSI-high was associated with improved OS (hazard ratio (HR) = 0.221, 95% confidence interval (CI): 0.026–0.870, p = 0.042), whereas the loss of DNA mismatch repair protein MutL homolog 1 (MLH1) expression was associated with worse OS (HR = 0.133, 95% CI: 0.001–1.152, p = 0.049). Our results suggest ddPCR is a promising tool for MSI detection. Given the opposing effects of MSI-high and MLH1 loss on OS, both ddPCR and IHC may be complementary for the prognostic assessment of CRC. Full article
(This article belongs to the Special Issue Feature Papers in Section "Cancer Biomarkers" in 2023–2024)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop